Cesium-131,most significant advancement in internal radiation therapy in 20 years

IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that it ranked 5th highest in share price performance for the 2014 calendar year, with a 192% increase, among all 2,417 listed companies on the NYSE Group, which includes the NYSE and the NYSE MKT.
IsoRay Chairman and CEO Dwight Babcock commented, “It is very rewarding to see the market begin to understand the tremendous potential benefits IsoRay and its products, utilizing IsoRay’s patented isotope Cesium-131, can offer to pediatric and adult patients suffering the ravages of cancer located in the brain, head and neck, lung, gynecological and prostate. As institutional study results are being peer reviewed and published, evidence is growing as to how well Cesium-131 kills cancer and its ability to provide an improved quality of life. Other institutional studies continue to accrue patients or are allowing their data to mature to a point that will be eligible for submittel to peer review. Cesium-131 not only successfully treats primary cancers but also those cancers that recur when the current standard of care has failed.”
Babcock said, “Leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer and I believe Cesium-131 is that solution.”
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.